Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery
Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
Stocks · News reference
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Growth Lead Sectors In Friday Trading As Defensives Trail
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Ozempic Market to Reach USD 113.95 Billion as Demand for GLP-1 Therapies Accelerates, Reports Mordor Intelligence
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Eli Lilly Enters Agreement with Hims & Hers to Expand Access to Obesity Medications
Eli Lilly and Company has reached an agreement with Hims & Hers to provide patients with direct access to its FDA-approved obesity medications, Zepbound and Foundayo, through the Hims & Hers platform.
BofA Securities Raises Eli Lilly Price Target
BofA Securities analyst Jason Gerberry maintained a 'Buy' rating on Eli Lilly and Company while increasing the price target from $1,497 to $1,557.
Zenith Epigenetics Announces Clinical Trial Collaboration with Eli Lilly
Zenith Epigenetics has executed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to study the combination of ZEN-3694 and Verzenio in patients with NUT carcinoma.